Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Fiche publication
Date publication
janvier 2024
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent, Dr BERTAUT Aurélie, Dr COUDERT Bruno, Pr COUTANT Charles, Dr LADOIRE Sylvain, Dr DESMOULINS Isabelle, Dr HENNEQUIN Audrey
Tous les auteurs :
Ilie SM, Briot N, Constatin G, Ilie A, Beltjens F, Ladoire S, Desmoulins I, Hennequin A, Bertaut A, Coutant C, Causeret S, Ghozali N, Coudert B, Arnould L
Lien Pubmed
Résumé
The persistence of residual tumour after neoadjuvant chemotherapy (NAC) in localised triple-negative breast cancer (TNBC) is known to have a negative prognostic value. However, different degrees of expression of some immunohistochemical markers may correlate with different prognoses.
Mots clés
immunohistochemical marker, neoadjuvant chemotherapy, prognostic biomarkers, residual disease, triple-negative breast cancer
Référence
Front Oncol. 2024 01 10;13:1309890